Fresh analysis suggests that patients who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who halt conventional diet and exercise programs.
Published data in a leading health publication shows that while overweight people frequently drop substantial amounts of their total mass while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month after stopping.
"Users buying such treatments need to be informed of the danger of rapid rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery means a reversion to original mass in about one and a half years.
Comparing Approaches
The research, which looked at 37 of trials involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with other pills.
Scientists note that individuals who shed pounds through lifestyle changes alone typically have a less rapid creep back—approximately 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Experts believe the mode of action of the jabs is key to understanding the amplified weight return.
These medications imitate a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations far above than normal might result in the body to produce less of its own natural hormone, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' leads to appetite is no longer kept in check, making overeating far more likely."
A Lifelong Disease?
Medical guidelines advise the injections for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
Professionals argue that, given the significant potential of weight regain, the treatment might need to be ongoing.
This view is echoed by pharmaceutical companies, who say that the findings "highlight the chronic character of obesity," akin to managing conditions like high blood pressure.
Patient Testimonies
Users who have stopped the medication report a sudden resurgence of cravings.
"It felt as if a switch activating and you're instantly starving," described an individual.
This difficulty is compounded if users have not established sustainable dietary or behavioural changes during treatment.
Growing Interest
Figures show that a significant number of adults in the UK have tried these injections in the last 12 months, with interest being substantial.
- Use is more common among females than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, experts caution that while GLP-1 drugs are potent tools for weight loss, they are not a magic fix and lasting health benefits hinges on combined behavioural management.
